Advertisement
Advertisement
VVOS
Vivos Therapeutics, Inc. Common Stock
1.14
USDSponsored
0.00
0.00%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
1.13
-0.01
-1.32%
VVOS Earnings Reports
Positive Surprise Ratio
VVOS beat 8 of 19 last estimates.
42%
Next Report
Next Week
Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
$6.58M
/-$0.49
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
+77.84%
/+75.00%
Vivos Therapeutics, Inc. Common Stock earnings per share and revenue
On --, VVOS reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 6.58 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Vivos Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Vivos Therapeutics, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Vivos Therapeutics, Inc. Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Vivos Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Vivos Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $6.58M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement